This Great-Performing Stock Just Got a Lot Better

Not long after I wrote about this big health care firm in December 2010, this stock began a nice hot streak. It's now up 31% in the past 12 months, compared with a 14% gain for the S&P 500 during the same time. This is undoubtedly a great-performing stock. But when I first suggested investing in this company, currently best known for its blockbuster rheumatoid arthritis drug Humira, I wasn't thinking much about what the stock might do in the next year or two. What I liked about it then, as I still do now, is how well it's likely to perform over a much longer time span. So even though the stock's already up 31%, . . . → Read More: This Great-Performing Stock Just Got a Lot Better